Tokyo-headquartered biopharma Sosei Heptares (TSE:4565) announced that it had won Licensing Deal of the Year and Executive of the Year at the inaugural Informa Pharma Intelligence Awards Japan.
A panel of experts from academia and business across Japan judged the awards series.
The judges selected Sosei Heptares’ potentially multibillion-dollar alliance with San Diego, California–based Neurocrine Biosciences for the licensing deal award. The two companies are working together to develop novel muscarinic receptor agonists for schizophrenia, dementia and other neurological conditions. Sosei Heptares announced the collaboration in November 2021.
Sosei Heptares could receive up to $2.6 billion in R&D funding and milestone payments while keeping rights to develop M1 muscarinic agonists in Japan for all indications.
The most advanced program involved in the partnership is HTL-0016878, a selective M4 agonist.
Neurocrine Biosciences inten…